Abstract: The invention relates to medicine and the chemical and pharmaceutical industry, in particular to antibiotic preparative forms. The inventive antimicrobial composition contains antibiotic selected from a group of lincosamides, broad-spectrum penicillins, cephalosporins, macrolides, tetracyclines, and lactulose at the active component ratio of 1:1-1:100. The mean particle size of lactulose ranges from 100 nm to 200 ?m. Said composition is embeddable in a solid state and in the form of a syrup or a suspension. When applicable, pharmaceutically acceptable excipients are added into the composition in such a way that it takes a form acceptable for peroral administration.
Type:
Grant
Filed:
August 25, 2005
Date of Patent:
July 31, 2012
Inventors:
Nikolai Alexandrovich Kiselev, Dmitry Sergeevich Chicherin
Abstract: The present invention relates to the use of an oral composition comprising meat extract and peptones, separately or in combination, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as Clostridium difficile. Such effects may include the failure of the integrity of the gut epithelial cells and diarrhoea as well as other COX-2 mediated effects.
Abstract: Disclosed is a method of regulating fluid flow for a targeted lung region. The method comprises injecting a therapeutic agent into the targeted lung region. The therapeutic agent induces a reaction in lung tissue of the targeted lung region or in a collateral pathway to the lung region to reduce collateral fluid flow into the targeted lung region. In one aspect, the method additionally comprises deploying a bronchial isolation device in the direct pathway to regulate fluid flow to the targeted lung region through the direct pathway. The therapeutic agent can comprise, for example, a sclerosing agent that induces a reaction that causes sclerosis in the lung tissue.
Type:
Grant
Filed:
February 25, 2005
Date of Patent:
June 26, 2012
Assignee:
Pulmonx Corporation
Inventors:
John McCutcheon, Antony J. Fields, David Peter Shaw
Abstract: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.
Abstract: The invention relates to superfine microparticles and nanoparticles and a process for their gentle preparation with exclusion of water or minimization of water and/or exclusion of plasticizers and/or reduced temperature load, in which a matrix material is subjected to a high-pressure homogenization process in an anhydrous or water-poor medium and/or at low temperatures, preferably room temperature (20° C.) and in particular below the freezing point of water, which leads to a gentle particle reduction with minimization of the impairment of the chemical stability of the homogenized material.
Type:
Grant
Filed:
July 10, 2000
Date of Patent:
June 19, 2012
Assignee:
Abbott GmbH & Co., KG
Inventors:
Rainer H. Müller, Karsten Krause, Karsten Mäder
Abstract: The invention relates to a composition for taking dietary fibers, which comprises 1 to 50% by weight, on the basis of the whole composition, of dietary fibers composed of water-soluble and hardly fermentable dietary fiber and water-soluble and fermentable dietary fiber, wherein the water-soluble and fermentable dietary fiber is contained in a proportion of 0.1 to 3 parts by weight per part by weight of the water-soluble and hardly fermentable dietary fiber. The composition remarkably ameliorates not only bowel movement frequency but also full consciousness, feeling of unsatisfied defecation, etc. and is hence useful as food for ameliorating bowel movement.
Abstract: A stable and taste masked pharmaceutical dosage form includes porous apatite grains and a drug entrapped in pores of said grains, wherein said grains have a size of 0.1-1000 ?m and said pores of said grains have an opening of 0.5-300 nm. A process for preparing the stable and taste masked pharmaceutical dosage form is also disclosed.
Type:
Grant
Filed:
March 16, 2004
Date of Patent:
May 22, 2012
Assignee:
Nanotrend Ino-Tech Inc.
Inventors:
Chang-Yi Lin, Yunn-Tzer Lu, Dean-Mo Liu
Abstract: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.
Abstract: This invention provides edible compositions comprising pharmaceutically or nutraceutically active agents in particulate form homogeneously dispersed in a fat matrix, such as chocolate or chocolate compound coating.
Abstract: This invention provides edible compositions comprising pharmaceutically or nutraceutically active agents in particulate form homogeneously dispersed in a fat matrix, such as chocolate or chocolate compound coating.
Abstract: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.
Abstract: This invention provides edible compositions comprising pharmaceutically or nutraceutically active agents in particulate form homogeneously dispersed in a fat matrix, such as chocolate or chocolate compound coating.
Abstract: The invention relates to new forms of salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.
Abstract: Provided are a method of injecting a visualizing material into a point in the vicinity of the Jung-Wan and a method of visualizing arrival of liquid agent in order to verify that the visualizing material injected arrives at internal organs. A point having the lowest electric resistance is found in the vicinity of Jung-Wan of the subject by using an electro acupuncture point detector. The visualizing material is injected into the point by means of an injecting instrument and then verified at least one point of the pancreas and the threadlike structures on top of the surface of the pancreas. The visualizing material is an alcian blue solution or a nanoparticle-containing solution labeled with fluorescent organic material.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
November 15, 2011
Assignees:
Seoul National University Industry Foundation, Mobase Co., Ltd.
Inventors:
Kwang Sup Soh, Cheon Joo Choi, Min Soo Kim, Baeck Kyoung Sung, Vyacheslav Ogay
Abstract: A method for helping pets recover from periods of strenuous activity includes providing a source of carbohydrates formulated to provide a readily available replenishment source of glycogen for the pet and providing a replenishment source of vitamins, minerals, and antioxidants which are expended at rates that are higher during the strenuous activity than during non-strenuous activity.
Type:
Grant
Filed:
March 5, 2003
Date of Patent:
October 11, 2011
Assignee:
Nestec, Ltd.
Inventors:
Monique Y. Sidebottom, Arleigh J. Reynolds
Abstract: Disclosed is a novel solid dosage unit, preferably in the form of a film or thin troche, containing at least one pharmaceutical agent, and its method of manufacture, which involves introduction of a fluid containing at least one non-volatile material, such as a polymeric film forming substance, a volatile carrier and at least one pharmaceutical agent into a depression or cavity comprising the major element of the packaging film for the finished dosage unit (s), and removing the volatile carrier from the cavity by exposure to radiant energy, whereby the remaining non-volatile residue comprises the desired dosage unit. The packaging film can be subsequently lidded by conventional sealing methods to produce packaged dosage units which are suitable for sublingual and other oral applications.
Abstract: A transdermal composition is disclosed which contains a blend of one or more polymers, one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures. The composition is substantially free of water and liquids which have a normal boiling point (a) optionally below processing temperatures and (b) greater than or equal to the temperature of the low molecular weight drugs. The composition does not suffer from the substantial loss of the lower molecular weight drug during production of the transdermal system. A transdermal composition is also disclosed which has one or more drugs, at least one of which has a low molecular weight and is liquid at or about room temperatures, and a polymer matrix including one or more high shear resistant polymers. The high shear resistant polymer(s) reduce the plasticizing effect of the low molecular weight drug, and has sufficient tack and shear for application to a human being.
Abstract: Novel acylglycerides are disclosed comprising mono-, di- and triacylglycerides characterized by predominantly containing the conjugated linoleic acids t9,c11- and c10,t12 octadecadienoic acids to the exclusion of 11,13-, 8,10- and trans,trans isomers.
Type:
Grant
Filed:
July 21, 2003
Date of Patent:
April 7, 2009
Assignee:
Aker Biomarine ASA
Inventors:
Gudmundur G. Haraldsson, Asgeir Saebo, Carl Skarie, Daria Jerome
Abstract: New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3?diindolylmethane (LTR-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia and endometriosis.
Abstract: New compositions are disclosed that comprise the phytochemical Diindolylmethane (DIM), as well as its precursor, Indole-3-carbinol (I3C), and cogener, 2-(Indol-3-ylmethyl)-3,3?diindolylmethane (LTr-1), acceptable carriers and/or excipients. These compositions are administered to prevent or reduce symptoms associated with mastalgia, endometriosis and HPV-related conditions including cervical dysplasia.